Ngā hua rapu - Ganesh Moorthy
- E whakaatu ana i te 1 - 10 hua o te 10
-
1
Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, <scp>ACP</scp>‐5862, Using a <scp>Physiologically‐Based Pharmacokinetic</scp> Modeling... mā Diansong Zhou, Terry Podoll, Yan Xu, Ganesh Moorthy, Karthick Vishwanathan, Joseph A. Ware, J. Greg Slatter, Nidal Al‐Huniti
I whakaputaina 2019Artigo -
2
-
3
Pharmacokinetics and Safety of Fluconazole in Young Infants Supported With Extracorporeal Membrane Oxygenation mā Kevin M. Watt, Daniel K. Benjamin, Ira M. Cheifetz, Ganesh Moorthy, Kelly C. Wade, P. Brian Smith, Kim L. R. Brouwer, Edmund V. Capparelli, Michael Cohen‐Wolkowiez
I whakaputaina 2012Artigo -
4
Characterization and antifungal activity of the yellow pigment produced by a Bacillus sp. DBS4 isolated from the lichen Dirinaria agealita mā Turki M. Dawoud, Naiyf S. Alharbi, Aswani M. Theruvinthalakal, Aswani Thekkangil, Shine Kadaikunnan, Jamal M. Khaled, Taghreed N. Almanaa, Karthikumar Sankar, I. Ganesh Moorthy, Khaled F Alanzi, Shyam Kumar Rajaram
I whakaputaina 2019Artigo -
5
Characterization and antifungal activity of the yellow pigment produced by a Bacillus sp. DBS4 isolated from the lichen Dirinaria agealita mā Dawoud, Turki M., Alharbi, Naiyf S., Theruvinthalakal, Aswani M., Thekkangil, Aswani, Kadaikunnan, Shine, Khaled, Jamal M., Almanaa, Taghreed N., Sankar, Karthikumar, Innasimuthu, Ganesh Moorthy, Alanzi, Khaled F, Rajaram, Shyam Kumar
I whakaputaina 2020Text -
6
Abstract CT007: PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations mā Timothy A. Yap, Seock‐Ah Im, Alison M. Schram, Adam Sharp, Judith Balmañà, Richard D. Baird, Jessica Brown, Maria Schwaederlé, Elizabeth A. Pilling, Ganesh Moorthy, Spiros Linardopoulos, Adam Dowson, Carol Pound, Edit Lukacs, Sabina Cosulich, Stephen J. Luen
I whakaputaina 2022Artigo -
7
A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies mā Trisha M. Wise‐Draper, Ganesh Moorthy, Mohamad A. Salkeni, Nagla Abdel Karim, Hala Elnakat Thomas, Carol A. Mercer, Muhammad S. Beg, Sue O’Gara, Olugbenga Olowokure, Hassana Fathallah, Sara C. Kozma, George Thomas, Olivier Rixe, Pankaj B. Desai, John C. Morris
I whakaputaina 2017Artigo -
8
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma mā Erika Hamilton, Judy S. Wang, Amit M. Oza, Manish R. Patel, Susanna V. Ulahannan, Todd M. Bauer, Janet L. Karlix, Jorge Zerón-Medina, Giulia Fabbri, Paola Marco‐Casanova, Ganesh Moorthy, Maureen M. Hattersley, Gillian M. Littlewood, Patrick D. Mitchell, Jamal Saeh, Gayle P. Pouliot, Kathleen N. Moore
I whakaputaina 2023Artigo -
9
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors mā Emerson A. Lim, Johanna C. Bendell, Gerald S. Falchook, Todd M. Bauer, Charles G. Drake, Jennifer H. Choe, Daniel J. George, Janet L. Karlix, Susanna V. Ulahannan, Kris F. Sachsenmeier, Deanna L. Russell, Ganesh Moorthy, Ben S. Sidders, Elizabeth A. Pilling, Huifang Chen, Maureen M. Hattersley, Mayukh Das, Rakesh Kumar, Gayle P. Pouliot, Manish R. Patel
I whakaputaina 2022Artigo -
10
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors mā Atish D. Choudhury, Celestia S. Higano, Johann S. de Bono, Natalie Cook, Dana E. Rathkopf, Kari B. Wisinski, Juan Martín-Liberal, Mark Linch, Elisabeth I. Heath, Richard D. Baird, Javier García-Carbacho, Miguel Quintela‐Fandino, Simon T. Barry, Elza C. de Bruin, Steve Colebrook, George Hawkins, Teresa Klinowska, Brijesh Maroj, Ganesh Moorthy, Peter G. Mortimer, Michele Moschetta, Myria Nikolaou, Liz Sainsbury, Geoffrey I. Shapiro, Lillian L. Siu, Aaron R. Hansen
I whakaputaina 2022Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Medicine
Adverse effect
Pharmacokinetics
Internal medicine
Pharmacology
Pharmacodynamics
Biochemistry
Cancer
Chemistry
Gastroenterology
Oncology
Nausea
Prostate cancer
Tolerability
Anesthesia
Antifungal
Biology
Combination therapy
Dermatology
Dosing
Fluconazole
Gene
Mucositis
Olaparib
Poly ADP ribose polymerase
Polymerase
Toxicity
ABTS
Abiraterone acetate
Active metabolite